搜索筛选:
搜索耗时1.5073秒,为你在为你在102,285,761篇论文里面共找到 607 篇相符的论文内容
类      型:
[会议论文] 作者:Peng Liu,Sunbin Ling,Xiao Xu, 来源:2019中国肿瘤学大会 年份:2019
Objective Glutamine synthetase(GS)level increases gradually with the development of hepatocellular carcinogenesis.However,its clinical relevance with HCC patients and influence on hepatocellular carci...
[会议论文] 作者:Kai Zheng,Xiuchun Yu,Ming Xu, 来源:2019中国肿瘤学大会 年份:2019
Objective Myxoid Liposarcoma(MLPS)is the most common type of liposarcoma,the clinical outcomes are rare reported.The purpose of this study was to make a suitable treatment for the MLPS in extremities...
[会议论文] 作者:Junnan Xu,Meinan Li,Tao Sun, 来源:2019中国肿瘤学大会 年份:2019
Objective To investigate the optimal anti-proliferative drugs of human breast cancer cell lines MCF-7,MDA-MB-231 and SK-BR-3 from the total extracts of Euphorbia fischeriana and their monomers,to obse...
[会议论文] 作者:Zhiyuan Xu,Can Hu,Xiangdong Cheng, 来源:2019中国肿瘤学大会 年份:2019
[会议论文] 作者:qiaoping zhu,Benhua Xu,Anchuan Li, 来源:2019中国肿瘤学大会 年份:2019
Objective The incidence of tumor deposit(TD)in colorectal cancer is 5%~45%,which is associated with high risk of local recurrence and distant metastasis....
[会议论文] 作者:YUCHEN WU,CONGCONG ZHU,YE XU, 来源:2019中国肿瘤学大会 年份:2019
[会议论文] 作者:Junfeng Shi,Jin Xu,Ge Ma, 来源:2019中国肿瘤学大会 年份:2019
Objective Breast cancer is a general type of cancer,which was first recognized by the Egyptians 3500 years ago.In the light of the expression of hormone receptor(HR)and human epidermal growth factor r...
[会议论文] 作者:Liming XU,Lujun Zhao,Ping Wang, 来源:2019中国肿瘤学大会 年份:2019
Objective Lung cancer is a type of malignant tumor with high morbidity and mortality.Due to its complicated etiology and clinical manifestations,no significant therapeutic advance has been made.Lung s...
[会议论文] 作者:Junnan Xu,Jingjing Wang,Tao Sun, 来源:2019中国肿瘤学大会 年份:2019
[会议论文] 作者:Shenyu Wei,Zhiyuan Xu,Xiangdong Cheng, 来源:2019中国肿瘤学大会 年份:2019
[会议论文] 作者:Hongmei Liu,Zongren Zhao,Haoyue Xu, 来源:2019中国肿瘤学大会 年份:2019
[会议论文] 作者:Junnan Xu,Fangying Li,Tao Sun, 来源:2019中国肿瘤学大会 年份:2019
[会议论文] 作者:Xu Tian,Wei-Qing Chen,Xiao-Ling Liu, 来源:2019中国肿瘤学大会 年份:2019
[会议论文] 作者:jie zhang,Xiaobing Miu,Xiaohong XU, 来源:2019中国肿瘤学大会 年份:2019
Objective As we all known,with the development of immunophenotypic and molecular genetics,the status of IPI is gradually declining....
[会议论文] 作者:lei zhu,Xiaozhou Yu,Wengui Xu, 来源:2019中国肿瘤学大会 年份:2019
[会议论文] 作者:Xiaofeng Wang,Xiangdong Cheng,Zhiyuan Xu, 来源:2019中国肿瘤学大会 年份:2019
Objective Cisplatin is the major chemotherapeutic drug in gastric cancer,especially for advanced gastric cancer.The tumor cells often develop resistance to chemotherapeutic drugs,which seriously affec...
[会议论文] 作者:Can Hu,Xu Zhiyuan,Cheng Xiangdong, 来源:2019中国肿瘤学大会 年份:2019
[会议论文] 作者:chenxi ma,Xishan Wang,Xu Guan, 来源:2019中国肿瘤学大会 年份:2019
Objective The BM incidence rate from CRC has increased in recent years,the occurrence of SREs,including bone pain,pathological fracture,possible rathiotherapy,spinal cord compression,fatal hypercalcem...
[会议论文] 作者:Chengwei Shi,Xiangdong Cheng,Zhiyuan Xu, 来源:2019中国肿瘤学大会 年份:2019
Objective Gastric cancer is the second leading cause of cancer-related deaths and the fifth most common malignancy worldwide.Gastric cancer(GC)is a common malignancy with low 5-year overall survival(O...
[会议论文] 作者:Yanyan Zhang,Shuyi Zhu,Xiumei Wang,Zhi Xu,Peipei Qian,Wenbo Sun,Yong Xu, 来源:2019中国肿瘤学大会 年份:2019
Objective Engagement of the programmed death(PD)-1 receptor on activated cells by its ligand(PD-L1)is a mechanism for suppression of activated T-lymphocytes....
相关搜索: